Genetic Background of the Sickle Cell Disease Pediatric Population of Dakar, Senegal, and Characterization of a Novel Frameshift β-Thalassemia Mutation [HBB: c.265_266del; p.Leu89Glufs2]

Sickle cell disease is a genetic disorder with a large variability in the pattern and severity of clinical manifestations. Different genetic modulators have been identified but very few epidemiologic data are available on these modifier genes in Senegal. This study aimed to determine their prevalenc...

Full description

Saved in:
Bibliographic Details
Published in:Hemoglobin 2017-03, Vol.41 (2), p.89-95
Main Authors: Gueye Tall, Fatou, Martin, Cyril, Malick Ndour, El Hadji, Déme Ly, Indou, Renoux, Céline, Chillotti, Louis, Veyrenche, Nicolas, Connes, Philippe, Madieye Gueye, Papa, Ndiaye Diallo, Rokhaya, Lacan, Philippe, Diagne, Ibrahima, Amadou Diop, Pape, Cissé, Aynina, Lopez Sall, Philomène, Joly, Philippe
Format: Article
Language:English
Subjects:
Adolescent
Anemia, Sickle Cell - genetics
beta-Thalassemia - genetics
Child
Child, Preschool
Female
Frameshift Mutation
glucose-6-phosphate dehydrogenase (G6PD) Betica
Hemoglobins - genetics
Hemoglobins, Abnormal - genetics
Humans
Life Sciences
Male
novel β-thalassemia (β-thal) mutation
Senegal
sickle cell disease
XmnI polymorphism
α-Thalassemia (α-thal)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sickle cell disease is a genetic disorder with a large variability in the pattern and severity of clinical manifestations. Different genetic modulators have been identified but very few epidemiologic data are available on these modifier genes in Senegal. This study aimed to determine their prevalence in a Senegalese sickle cell disease pediatric population. The following genetic parameters were genotyped in 295 sickle cell disease children of the Dakar pediatric hospital: sickle cell disease genotype [β S /β S (HBB: c.20A>T), β S /β C (HBB: c.19G>A), β S /β 0 -thalassemia (β 0 -thal)], XmnI polymorphism, the five most common α-thalassemia (α-thal) deletions and the A(-) and Betica glucose-6-phosphate-dehydrogenase (G6PD) deficient variants. Despite very few β S /β C and β S /β 0 -thal children (1.0% each), a novel frameshift β 0 -thal mutation was characterized: HBB: c.265_266del; p.Leu89Glufs*2. The -α 3.7 (rightward) deletion was the only α-thal deletion identified in this cohort (12.0% allelic frequency). Most of β S /β S patients (61.9%) were homozygous for the XmnI polymorphism and assumed to carry a Senegal/Senegal β S haplotype. The remaining haplotypes were predominantly of the Benin type. While the Betica G6PD variant was quite frequent (13.0%), a low frequency of the A(-) variant was detected (1.0-2.0%). The systematic genotyping of the -α 3.7 deletion and of the G6PD Betica variant in sickle cell disease patients from Senegal could be useful to identify patients at risk for several complications, such as cerebral vasculopathy, where it has been demonstrated that a normal α-globin genotype and G6PD deficiency are predisposing factors. These patients should be eligible for a transcranial Doppler examination that is not routinely offered in Senegal.
ISSN:0363-0269
1532-432X
DOI:10.1080/03630269.2017.1339610